Archive - Pain in the Access

MFN Update, Part 1: The Framework

MFN is taking shape, but US price impacts may be limited for now

May 26 • John Jarvis

Market Access: A Primer

Your drug just got approved! Now who’s going to pay for it, prescribe it, and use it?

May 19 • John Jarvis

What Did the Inflation Reduction Act (IRA) Change?

And how does it affect value and evidence strategies for biopharma

May 11 • John Jarvis

The Patient Choice Era

In the next competitive era, drug manufacturers will need to prove value to patients

May 8 • John Jarvis

September 2025

Most-Favored-Nations and the Warped Curve

The uneven consequences of most-favored-nations (MFN) pricing

Sep 25, 2025 • John Jarvis

Pharma's Bundle Strategy

Pharma's expanding moat: from molecules to bundles

Sep 21, 2025 • John Jarvis

PBMs and the App Store

Apple taxes apps. PBMs tax drugs. Lessons from the App Store for pharma

Sep 11, 2025 • John Jarvis

Welcome to Pain in the Access

Connecting value, access, and evidence to business strategy in pharma

Sep 9, 2025 • John Jarvis

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts